BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 139,200 shares, a decline of 47.9% from the August 15th total of 267,200 shares. Based on an average daily volume of 291,500 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of BioLineRx

Institutional investors and hedge funds have recently made changes to their positions in the business. PVG Asset Management Corp acquired a new position in shares of BioLineRx during the 2nd quarter worth about $70,000. CVI Holdings LLC bought a new stake in shares of BioLineRx during the 2nd quarter worth approximately $462,000. Finally, NorthRock Partners LLC acquired a new stake in BioLineRx in the fourth quarter valued at about $27,000. Institutional investors own 1.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a report on Wednesday, May 29th. StockNews.com upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.

BioLineRx Stock Down 1.4 %

BLRX stock traded down $0.01 during mid-day trading on Friday, reaching $0.62. The company had a trading volume of 85,897 shares, compared to its average volume of 345,633. BioLineRx has a one year low of $0.51 and a one year high of $2.30. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The stock’s 50-day simple moving average is $0.71 and its two-hundred day simple moving average is $0.78.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. On average, sell-side analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.